Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17007985 | 1.00 | GAA (0.36) | GAASMN1; SMN2MAOBAOC3MAPT | |
| SCHEMBL18889915 | 0.81 | ALDH1A1 (0.40) | SMN1; SMN2ALDH1A1SLC6A4 | |
| SCHEMBL24749681 | 0.75 | MAPT (0.33) | MAOBAOC3MAPTALDH1A1SLC6A4 | |
| SCHEMBL30829775 | 0.74 | ALDH1A1 (0.47) | GAASMN1; SMN2MAOBFFAR4ALDH1A1 | |
| SCHEMBL1020456 | 0.74 | ALDH1A1 (0.47) | GAASMN1; SMN2MAOBFFAR4ALDH1A1 | |
| SCHEMBL4633428 | 0.73 | MTNR1A (0.46) | SMN1; SMN2ALDH1A1SLC6A4MAOA | |
| SCHEMBL17007988 | 0.72 | DHODH (0.34) | DHODH | |
| SCHEMBL27203860 | 0.72 | DHODH (0.34) | DHODH | |
| SCHEMBL29854727 | 0.72 | DHODH (0.34) | DHODH | |
| SCHEMBL17007990 | 0.72 | DHODH (0.34) | DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3114129-A1 | IMIDAZOPYRIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2017-01-11 | — | — | EP | disclosed |
| US-9409922-B2 | Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-09 | — | — | US | disclosed |
| US-9409922-B2 | Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-09 | — | — | US | disclosed |
| US-9409922-B2 | Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-09 | — | — | US | disclosed |
| WO-2015126751-A1 | IMIDAZOPYRIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-27 | — | — | WO | disclosed |
| WO-2015126751-A1 | IMIDAZOPYRIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-27 | — | — | WO | disclosed |
| US-20150232480-A1 | Imidazopyridine Macrocycles as Inhibitors of Human Immunodeficiency Virus Replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2015-08-20 | — | — | US | disclosed |
| US-20150232480-A1 | Imidazopyridine Macrocycles as Inhibitors of Human Immunodeficiency Virus Replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2015-08-20 | — | — | US | disclosed |
| US-20150232480-A1 | Imidazopyridine Macrocycles as Inhibitors of Human Immunodeficiency Virus Replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232480-A1 | Imidazopyridine Macrocycles as Inhibitors of Human Immunodeficiency Virus Replication | EIF2AK2, MAVS, TYMP | GAA 966/4885SMN1; SMN2 2620/4885MAOB 2777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.